Imarx Therapeutics Inc - Current report filing (8-K)
August 14 2008 - 4:10PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 14, 2008
IMARX THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
0001-33043
|
|
86-0974730
|
(State or other Jurisdiction of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
|
|
|
1730 East River Road, Suite 200, Tucson, AZ
|
|
85718-5893
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code:
(520) 770-1259
|
|
(Former name or former address if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 2.02 Results of Operations and Financial Condition.
The following information is furnished pursuant to Item 2.02, Results of Operations and
Financial Condition. On August 14, 2008, we issued a press release announcing our operating
results for the second quarter ended June 30, 2008. The text of the press release is furnished as
Exhibit 99.1 to this Form 8-K.
The information in Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not
be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 (the Exchange
Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as
expressly set forth by specific reference in such filing.
ITEM 9.01 Financial Statements and Exhibits.
99.1 Press Release issued by ImaRx Therapeutics, Inc. on August 14, 2008.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: August 14, 2008
|
|
|
|
|
|
IMARX THERAPEUTICS, INC.
|
|
|
/s/ KEVIN ONTIVEROS
|
|
|
By: Kevin Ontiveros
|
|
|
Vice President, Legal Affairs,
General Counsel and Secretary
|
|
|
3
EXHIBIT INDEX
|
|
|
|
|
Exhibit Number
|
|
Description
|
|
|
|
|
|
|
99.1
|
|
|
Press Release issued by ImaRx Therapeutics, Inc. on August 14, 2008.
|
4
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jul 2023 to Jul 2024